Share Name Share Symbol Market Type Share ISIN Share Description
Woodford Patient Capital Trust Plc LSE:WPCT London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.50p +4.62% 34.00p 33.60p 33.90p 34.60p 32.60p 32.65p 4,500,306 16:35:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -3.8 -0.5 - 309

Woodford Patient Capital Share Discussion Threads

Showing 10401 to 10420 of 11100 messages
Chat Pages: Latest  420  419  418  417  416  415  414  413  412  411  410  409  Older
DateSubjectAuthorDiscuss
13/9/2019
07:36
Double bottom on chart. Should see 60p soon
volsung
13/9/2019
07:15
Yes, here: https://www.theaic.co.uk/companydata/CC8SU/performance but it's essentially the Morningstar chart, which I can't drop into here.
jonwig
13/9/2019
07:05
Aic website will have such charts
scrapheap
13/9/2019
07:04
Citywire says WEIF funded RUTH: https://citywire.co.uk/funds-insider/news/woodfords-frozen-fund-meets-cash-promise-to-proton-beam-stock/a1267352?ref=citywire-money-latest-news-list The shares are being issued at £1.76 each, below the range of £2.10 to £2.45 at which they nominally trade. Recent Woodford Investment Management filings suggest Link Fund Solutions, administrator of all Woodford's funds, is valuing the shares at £2. So this is probably the company which is responsible for yesterday's NAV announcement. Also: Rutherford can still draw down a further £32.5 million in funding from Woodford before the end of August next year. They better be quick: WIM won't exist by then ... by Christmas, even?
jonwig
13/9/2019
06:46
CC2014 - the only place I've found with a share price vs NAV chart is this one: http://tools.morningstar.co.uk/uk/cefreport/default.aspx?SecurityToken=f00000vfud but the image doesn't seem to be transferable. If there are any other sites, please let me know.
jonwig
12/9/2019
23:31
CC2014, Yes, the rock and the hard place, unquoted limit and gearing limit. When WPCT announced last Friday that its overdraft provider now has a veto on Woodford making any further investments, it said the overdraft was £113.7m, which is 12.5p a share, while NAV that day was 73.1p, giving, as the RNS stated, gearing of 17.1%. Today's reported NAV was 72.85p, but with the 4p hit we're looking at 68.85p. If the overdraft is still 12.5p a share as reported last Friday, gearing goes up to 18.2%. Back in June, when the board announced it had "agreed a schedule with Woodford Investment Management Ltd to reduce the level of gearing to below 10% within six months," gearing was 16.8%. A quarter of the way through the six months, far from reducing gearing, Woodford has so far managed to increase it from 16.8% to 18.2%.
henchard
12/9/2019
23:05
Tomorrow the published NAV will begin with a 6 and what we really need is Jon to find a way to get a chart of the NAV into the header. On the one hand I guess this is one way to try and keep the unquoted percentage below the limit by valuing them at reality. However, on the other the question of gearing is going to raise it's head again.
cc2014
12/9/2019
21:53
It will be interesting to see the price movement tomorrow on this news. Are these NAV cuts now fully discounted in the price, or will this news still come as a shock to some? Nothing at all would surprise me given owners of this stock such as the cretins on this board who purportedly have been buying on the way down. They’ve had a chance to avoid this garbage were they to have listened to the more enlightened posters here - good God, man, they’ve had two sodding years to get out. Are they incapable of learning anything? I missed a further short at 48p yesterday and 47p today. Doing other things. You can’t win them all, but at least I’m not long (partly because I have an IQ over 60).
psychochomper
12/9/2019
21:23
I should add that whilst I think oxford nanopore are spending a lot of money, it will be a rare winner. Valuation of course is another matter
dr biotech
12/9/2019
20:01
Going to zero.
topvest
12/9/2019
18:55
4p = over £36m, but still the tip of an iceberg. Agree SpectoAcc and Jonwig, we'll see a slow attrition of the NAV. Like the banks post-GFC, imo, slowly deflating their balance sheets, knowing damn well they'd be insolvent if they took the writedowns in one hit.
henchard
12/9/2019
18:40
Only 4p? Is this the new incrementalism - small steps so nobody notices.
jonwig
12/9/2019
18:33
Benevolent AI, Oxford Nanopore or Industrial Heat surely got to be the shortlist, as it'll have to be one of the biggest holdings to have such an impact on WPCT's NAV. I'll go for a further writedown of IH.
henchard
12/9/2019
18:24
Maybe we should have a sweepstake on which company has whacked down WPCT's NAV to the tune of 4p a share!
henchard
12/9/2019
18:23
Their HQ in Oxford Science Park??? Not my idea of swish
williamcooper104
12/9/2019
18:20
After hours RNS: Asset Valuation Link Fund Solutions Limited ("Link"), through its Fair Value Pricing Committee, is responsible for the valuation of the portfolio of Woodford Patient Capital Trust plc (the "Company"). Link, with the support of an independent valuation firm (IHS Markit), undertakes the valuation of the Company's unquoted assets in accordance with the Financial Reporting Standard (FRS) 102 and International Private Equity and Venture Capital Guidelines (IPEV). The Board has been notified by Link that Link intends to reduce the valuation of one of the Company's holdings. This valuation change is expected to impact the Company's net asset value by approximately 4.0 pence per share and will be reflected in the Company's net asset value as at close of business 12 September 2019 (which will be announced to the market on 13 September 2019). The Board is unable to comment further on this revaluation at this time due to confidentiality obligations, but it will provide a further update to the market when able to do so.
henchard
12/9/2019
15:51
Wouldn’t really say they are R&D..more product development. Labs make the chemicals used to treat the sample before analysis. It’s the analysis part that is cutting edge, I didn’t see that R&D dept. Nanopore make instruments rather than drugs, so it’s a bit different to a pharma lab. No GMP yet which makes life simpler.
dr biotech
12/9/2019
13:11
Article on citywire saying the price is rallying as it was the equity income fund not WPCT which funded the rutherford new monies. "Patient capital rallies as cash pledge to top stock falls on Woodford fund"
scrapheap
12/9/2019
12:16
I've recently spent some time in the labs at Oxford Nanopore - they are a nice bunch. Their HQ is pretty swish, but I didn't really get the impression that they are about to become a multibillion pound company. I really tend to deal with the science rather than commercial so I could well be wrong, but I had the feeling that some of their offerings were more miss than hit. Of course its very early days for that sort of tech too. They had quite a lot of new equipment in their labs - a lot of the startups I've been too have tended to buy it second hand. I did think that perhaps they are spending more than most in a similar position. Of course if woodford et al stumped up a lot of money early doors then thats what happens.
dr biotech
12/9/2019
05:57
daffy - true, but I thought the commitment to fund RUTH was from WIM, rather than WPCT. If WPCT is a funder or co-funder, they will surely have to RNS it? Doesn't mean they will, though! diku - pictures are prorogued!
jonwig
Chat Pages: Latest  420  419  418  417  416  415  414  413  412  411  410  409  Older
Your Recent History
LSE
WPCT
Woodford P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191017 20:09:17